Generate Biomedicines (GENB) investor relations material

Vision and platform strategy

• Focus on programmable biology to create transformative medicines beyond the reach of traditional technologies.

• Integrated computational and biohardware innovation stack enables intentionality at scale in drug design.

• Platform leverages machine learning and proprietary data cycles to accelerate and improve therapeutic discovery.

• Modular capabilities include affinity optimization, conditional binding, viral neutralization, and T-cell activation.

• Strategic collaborations with Amgen, Novartis, MD Anderson, and Roswell Park support platform validation and expansion.

Pipeline and clinical programs

• Five clinical-stage or clinic-ready molecules, including GB-0895 (anti-TSLP mAb), GB-4362 (MMAE toxin neutralizer), and GB-5267 (MUC16 CAR-T).

• GB-0895 is the first next-gen anti-TSLP mAb to enter global Phase 3, designed for twice-annual dosing with a 98-day half-life.

• GB-4362 targets toxicity reduction in MMAE-based ADCs, with initial focus on metastatic urothelial cancer.

• GB-5267 is an IL-18 armored CAR-T for advanced ovarian cancer, partnered with Roswell Park.

• Multiple preclinical programs and confidential collaborations are ongoing.

Clinical data and differentiation

• GB-0895 demonstrated deep, sustained biomarker reductions and a clean safety profile in Phase 1 asthma trials.

• Single 300mg dose of GB-0895 over 6 months matched or exceeded biomarker reductions seen with monthly tezepelumab.

• GB-0895 has the longest known half-life among TSLP therapies and supports 6-month dosing.

• GB-4362 preclinical data show effective MMAE neutralization and reduction of associated toxicities without impacting anti-tumor efficacy.

• GB-5267 preclinical models show superior tumor killing and persistence compared to clinical CARs.